Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
Price:
23.92 USD
-3.86%
Market Closed
Updated:
May 29, 2024
Arrowhead Pharmaceuticals Inc
Additional Paid In Capital
|
Arrowhead Pharmaceuticals Inc
Additional Paid In Capital Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Additional Paid In Capital Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
|
Additional Paid In Capital
$1.8B
|
CAGR 3-Years
21%
|
CAGR 5-Years
22%
|
CAGR 10-Years
17%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Additional Paid In Capital
$20.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Additional Paid In Capital
$6.8B
|
CAGR 3-Years
19%
|
CAGR 5-Years
22%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Additional Paid In Capital
$7.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
3%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Additional Paid In Capital
$11.9B
|
CAGR 3-Years
20%
|
CAGR 5-Years
23%
|
CAGR 10-Years
18%
|
See Also
What is Arrowhead Pharmaceuticals Inc's Additional Paid In Capital?
Additional Paid In Capital
1.8B
USD
1.8B
USD
Based on the financial report for Mar 31, 2024, Arrowhead Pharmaceuticals Inc's Additional Paid In Capital amounts to 1.8B USD.
What is Arrowhead Pharmaceuticals Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
17%
17%
Over the last year, the Additional Paid In Capital growth was 40%. The average annual Additional Paid In Capital growth rates for Arrowhead Pharmaceuticals Inc have been 21% over the past three years , 22% over the past five years , and 17% over the past ten years .
You don't have any saved screeners yet
